Novavax NVAX posted earnings per share of 99 cents in second-quarter 2024, missing the Zacks Consensus Estimate of $1.82. However, earnings rose 71% year over year.
Revenues in the quarter amounted to $415.5 million, also missing the Zacks Consensus Estimate of $453.7 million. The top line declined 2% on a year-over-year basis.
Quarter in Detail
In the reported quarter, the company recorded $19.9 million in product sales compared with $285.2 million in the year-ago quarter. While this reported figure did beat our model estimates of around $15 million, it missed the Zacks Consensus Estimate of $26 million.
During the quarter, NVAX recorded $395.6 million in licensing, royalties and other revenues compared with the year-ago quarter's revenues of $2.2 million. This figure includes $391 million associated with the upfront payment of $500 million received by management as part of the recently signed agreement with pharma giant Sanofi SNY for its protein-based COVID-19 vaccine, Nuvaxovid.
Management did not record any grant revenues during the quarter. Management recorded $137.1 million as grant revenues in the year-ago quarter.
In the reported quarter, research and development (R&D) expenses were $107 million, down 51% year over year. The downside was caused by a reduction in clinical and manufacturing spending during the quarter.
Selling, general and administrative (SG&A) expenses were up 8% year over year to $101 million, primarily due to certain fees paid in association with signing the Sanofi Agreement.
As of Jun 30, 2024, the company had $1.1 billion of cash and cash equivalents compared with $496 million as of Mar 31, 2024.
Guidance
For 2024
Novavax expects total revenues in the range of $700-$800 million in 2024, a cut down from its previously-issued guidance of $970 million to $1.17 billion (which includes nearly $70 million in equity investment). This fall in guidance is likely due to lower COVID-19 vaccine uptake in ex-U.S. markets.
This revised guidance includes nearly $425 million in licensing, royalties and other revenues. This includes $400 million of revenue recognition associated with the $500 million upfront payment from the Sanofi agreement and the rest in royalty and other revenues from partner-related activities.
It expects full-year product revenue guidance to be $275-$375 million.
The company maintained its full-year combined R&D and SG&A expenses in the band of $700-$750 million.
Beyond 2024
Management issued new guidance on combined R&D and SG&A expenses for the full years 2025 and 2026. It now targets the combined expenses to be below $500 million for 2025 and below $350 million for 2026. It also expects a portion of the costs of both these years to be reimbursed by Sanofi.
The remaining $100 million of the upfront payment from Sanofi will be evenly split across 2025 and 2026.
Despite the curtailed guidance and lower-than-expected results, Novavax's shares were up 9% on Aug 8, likely due to the reduction in operating expenses beyond 2024. Year to date, the stock has surged 143.3% against the industry's 3.5% fall.
Image Source: Zacks Investment Research
Recent Updates
In May, NVAX signed a multi-billion-dollar deal with Sanofi. Beginning next year, the company will gain rights to co-market Nuvaxovid globally, except in certain countries where Novavax has existing partnership agreements. The France-based drugmaker also has the sole license to develop and market the Novavax vaccine in combination with its influenza vaccine.
In return, Sanofi will make an upfront payment of $500 million to Novavax and up to $700 million in milestone payments, totaling up to $1.2 billion. It will be eligible to receive tiered double-digit percentage royalty payments on sales by Sanofi of Nuvaxovid, Sanofi's influenza-COVID combination vaccine and any other combination vaccines that Sanofi may develop, including Nuvaxovid.
Both companies will still have the right to develop their own combined COVID-19-influenza combination vaccines and adjuvanted products at their own cost. In addition to the above deal, Novavax also received an equity investment of nearly $70 million from Sanofi in exchange for a 4.9% stake.
Novavax has submitted two regulatory filings with the FDA — one seeking to obtain an emergency use authorization (EUA) for its updated 2024-2025 formula COVID-19 vaccine and another seeking full approval for the COVID-19 vaccine. While the decision for the first filing is expected to be received before the start of the 2024-2025 vaccination season, a final decision for the second filing is expected by April 2025.
Management is also on track to initiate a late-stage study on its COVID-19-Influenza Combination (CIC) vaccine and standalone influenza vaccines by this year's end. It intends to report data from this study in mid-2025.
Zacks Rank & Key Picks
Novavax currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector include Entrada Therapeutics and Fulcrum Therapeutics FULC, each sporting a Zacks Rank #1 (Strong Buy).
In the past 60 days, estimates for Entrada Therapeutics' 2024 loss per share have improved from 14 cents to 13 cents. Estimates for 2025 have improved from $3.44 to $3.21 during the same period. Year to date, shares of Entrada Therapeutics have lost 4.2%.
Earnings of Entrada Therapeutics beat estimates in two of the last four quarters while missing the mark on two other occasions. Entrada delivered a four-quarter average earnings surprise of 42.18%.
In the past 60 days, estimates for Fulcrum Therapeutics' 2024 loss per share have improved from $1.24 to 48 cents. Estimates for 2025 have improved from $1.71 to $1.51 during the same period. Year to date, shares of Fulcrum Therapeutics have risen 32.5%.
Earnings of Fulcrum Therapeutics beat estimates in each of the last four quarters. Fulcrum delivered a four-quarter average earnings surprise of 393.18%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.